SPIRO THEOHARAKIS: Open Payments
NPI 1124004056 · SMITHTOWN, NY. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$517 in 20 payments from 8 companies in 2025. Trend: 2023 $218 · 2024 $240 · 2025 $517
Food & beverage: $517
| Company | Payments | Amount |
|---|---|---|
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 3 | $179 |
| Neurocrine BioSciences, Inc. | 10 | $170 |
| Alkermes, Inc. | 2 | $38 |
| Axsome Therapeutics, Inc. | 1 | $35 |
| E.R. Squibb & Sons, L.L.C. | 1 | $27 |
| Otsuka America Pharmaceutical, Inc. | 1 | $24 |
| Teva Pharmaceuticals USA, Inc. | 1 | $23 |
| Corium, LLC | 1 | $22 |
Products named: CAPLYTA, INGREZZA, Auvelity, COBENFY, REXULTI, AUSTEDO XR, Azstarys, LYBALVI.
Industry payments across NY — which companies pay providers there.
